AMA strengthens policy to highlight risks of kratom products

| 2 Min Read

CHICAGO — At its annual meeting, the American Medical Association (AMA) expanded its policy on kratom products to underscore the potential harms to children and adolescents and highlight concerns about products containing concentrated 7-hydroxymitragynine—known as 7-OH—a potent opioid-like compound found naturally only in trace amounts in the kratom plant. 

Increasingly, manufacturers are extracting and concentrating 7-OH for sale in products that can be significantly more potent than traditional kratom leaf. These concentrated products may carry heightened risks of addiction, overdose, and other serious health harms. Many are marketed in forms that appeal to young people, including flavored gummies, brightly colored packaging, and other candy-like presentations. Such marketing practices have coincided with increasing reports of pediatric exposures to poison centers and greater access to these products by minors.

The policy adopted by the AMA calls for a ban on the sale, distribution, or marketing of 7-OH products and similar derivatives. It also urges the U.S. Food and Drug Administration (FDA) and state legislatures to classify 7-OH kratom products as adulterated or misbranded when sold in child-friendly forms and prohibit their availability in retail stores and online platforms accessible to minors. 

The AMA continues to recommend that the safety and efficacy of kratom and its derivatives should be determined through rigorous scientific research and clinical trials. Any determination regarding the marketing, sale, prescribing, or potential regulation under the Controlled Substances Act should be based on evidence and review by appropriate regulatory authorities.

“The AMA strongly supports efforts to educate parents, young people, and communities about the risks associated with concentrated 7-OH products,” said Dr. Melissa J. Garretson, a member of the AMA Board of Trustees. “While research continues, we cannot ignore the growing availability of unregulated products marketed in ways that appeal to children and adolescents. Concentrated 7-OH products are being sold in forms that can resemble candy and other treats, creating unnecessary risks for young people. We share the FDA’s concerns and support policies that protect children from exposure to these potentially harmful products.”

Media Contact

AMA Media & Editorial

Phone: (312) 464-4430

[email protected]

About the American Medical Association

The American Medical Association is the physicians’ powerful ally in patient care. As the only medical association that convenes 190+ state and specialty medical societies and other critical stakeholders, the AMA represents physicians with a unified voice to all key players in health care.  The AMA leverages its strength by removing the obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises and, driving the future of medicine to tackle the biggest challenges in health care.

FEATURED STORIES

Patient in hospital bed

Nurse practitioners’ care linked to 11% longer stays in the ED

| 4 Min Read
Two healthcare workers in conversation

Mid-career physicians report higher burnout rates

| 6 Min Read
Patient in a wheelchair

Shape your state’s hardship exemptions to Medicaid work requirements

| 7 Min Read
Doctor with reassuring hand on smiling patient

What doctors want patients to know about lupus

| 13 Min Read